Edgewise Therapeutics has announced the publication of the article, “Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy,” in the Journal of Clinical Investigation.
The article discusses the biology behind EDG-5506, an oral small-molecule muscle stabilizer aimed at protecting susceptible muscle fibers from the damage that occurs as a result of everyday activities in people living with Becker and Duchenne muscular dystrophy.
“This article illuminates the biology behind EDG-5506, demonstrating that modulation of fast skeletal muscle contraction protects against muscle injury, degeneration and fibrosis in models of DMD. Importantly, even 15% inhibition provides maximum and robust protection of skeletal muscles and was associated with increases in strength and physical activity in mouse and dog models of DMD.”Alan Russell, Ph.D., Chief Scientific Officer of Edgewise and senior author of the article
“This peer-reviewed publication provides further scientific validation for our approach, and these observations appear to translate to individuals with muscular dystrophy. We are excited about the potential of EDG-5506 for individuals affected by DMD and Becker muscular dystrophy, who are currently underserved with limited treatment options.”Kevin Koch, Ph.D., President and Chief Executive Officer
Edgewise is currently recruiting for two Phase 2 clinical trials:
- CANYON Clinical Trial for Becker muscular dystrophy (NCT05291091), with trial sites in the United States, United Kingdom and the Netherlands
- LYNX Clinical Trial for Duchenne muscular dystrophy (NCT5540860), with trial sites in the United States